Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9392474 | 1.00 | GAA (0.60) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL518197 | 1.00 | GAA (0.60) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL24111241 | 0.84 | GAA (0.44) | GAA | |
| SCHEMBL14159811 | 0.84 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL1271608 | 0.83 | GAA (0.54) | GAANFKB1NFKB2RELA | |
| SCHEMBL4915249 | 0.83 | GAA (0.54) | GAANFKB1NFKB2RELA | |
| SCHEMBL1036703 | 0.83 | GAA (0.54) | GAANFKB1NFKB2RELA | |
| SCHEMBL8357051 | 0.82 | GAA (0.50) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL19824266 | 0.81 | GAA (0.51) | GAANFKB1NFKB2RELABTK | |
| SCHEMBL9846514 | 0.79 | GAA (0.49) | GAANFKB1NFKB2RELABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240263-A1 | MACROCYCLIC RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023133543-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3387445-B1 | ISOBARIC MASS LABELS | ELECTROPHORETICS LTD (GB) | 2023-02-08 | — | — | EP | disclosed |
| US-10363237-B2 | Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-30 | — | — | US | disclosed |
| US-20160256432-A1 | COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-09-08 | — | — | US | disclosed |
| EP-2200564-B1 | COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE | UNIV CALIFORNIA (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9321743-B2 | Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-04-26 | — | — | US | disclosed |
| US-9133235-B2 | Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders | OCERA THERAPEUTICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133235-B2 | Macrocyclic antagonists of the motilin receptor for treatment of gastrointestinal dysmotility disorders | OCERA THERAPEUTICS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-02-27 | — | — | US | disclosed |
| EP-1578735-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | Pfizer Limited (GB) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004087666-A1 | NOVEL N-SUBSTITUTED 2-AMINOPYRIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1368349-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002068420-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | disclosed |
| WO-1994022841-A1 | ALKYLAMINO SUBSTITUTED TRIAZINEDIONES, TRIAZINEMONOTHIONES AND TRIAZINEDITHIONES | TOCRIS COOKSON LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10363237-B2 | Compositions and methods of inhibiting N-acylethanolamine-hydrolyzing acid amidase | NAAA, NAPEPLD, FAAH | GAA 300/4885NFKB1 3780/4885NFKB2 3858/4885 |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | GAA 325/4885NFKB1 2830/4885NFKB2 3624/4885 |
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | GAA 392/4885NFKB1 2043/4885NFKB2 2756/4885 |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | GAA 325/4885NFKB1 2830/4885NFKB2 3624/4885 |
| US-20160256432-A1 | COMPOSITIONS AND METHODS OF INHIBITING N-ACYLETHANOLAMINE-HYDROLYZING ACID AMIDASE | NAAA, NAPEPLD, FAAH | GAA 300/4885NFKB1 3780/4885NFKB2 3858/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | GAA 408/4885NFKB1 2684/4885NFKB2 3563/4885 |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | GAA 306/4885NFKB1 4693/4885NFKB2 4687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.